PRECISION BIOSCIENCES INC (DTIL) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does PRECISION BIOSCIENCES INC Do?
Precision BioSciences, Inc., a clinical stage gene editing company, develops vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which a specific type of immune cell, called a T cell, is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina. PRECISION BIOSCIENCES INC (DTIL) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Michael Amoroso and employs approximately 200 people. With a market capitalization of $141M, DTIL is one of the notable companies in the Healthcare sector.
PRECISION BIOSCIENCES INC (DTIL) Stock Rating — Hold (April 2026)
As of April 2026, PRECISION BIOSCIENCES INC receives a Hold rating with a composite score of 32.9/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.DTIL ranks #1,849 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, PRECISION BIOSCIENCES INC ranks #187 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
DTIL Stock Price and 52-Week Range
PRECISION BIOSCIENCES INC (DTIL) currently trades at $6.89. The stock gained $0.28 (4.3%) in the most recent trading session. The 52-week high for DTIL is $8.82, which means the stock is currently trading -21.8% from its annual peak. The 52-week low is $3.53, putting the stock 95.3% above its annual trough. Recent trading volume was 189K shares, suggesting relatively thin trading activity.
Is DTIL Overvalued or Undervalued? — Valuation Analysis
PRECISION BIOSCIENCES INC (DTIL) carries a value factor score of 15/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.68x, versus the sector average of 2.75x. The price-to-sales ratio is 243.38x, compared to 1.66x for the average Healthcare stock.
At current multiples, PRECISION BIOSCIENCES INC trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.
PRECISION BIOSCIENCES INC Profitability — ROE, Margins, and Quality Score
PRECISION BIOSCIENCES INC (DTIL) earns a quality factor score of 18/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -89.2%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -53.3% versus the sector average of -33.1%.
On a margin basis, PRECISION BIOSCIENCES INC reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -90114.4% (sector: -66.1%). Net profit margin stands at -92977.2%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -100.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
DTIL Debt, Balance Sheet, and Financial Health
PRECISION BIOSCIENCES INC has a debt-to-equity ratio of 67.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 13.32x, indicating strong short-term liquidity. Total debt on the balance sheet is $22M. Cash and equivalents stand at $45M.
DTIL has a beta of 0.68, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for PRECISION BIOSCIENCES INC is 39/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.
PRECISION BIOSCIENCES INC Revenue and Earnings History — Quarterly Trend
In TTM 2026, PRECISION BIOSCIENCES INC reported revenue of $636,000 and earnings per share (EPS) of $-3.56. Net income for the quarter was $-82M. Gross margin was 100.0%. Operating income came in at $-86M.
In FY 2025, PRECISION BIOSCIENCES INC reported revenue of $34M and earnings per share (EPS) of $-3.56. Net income for the quarter was $-46M. Revenue grew -50.1% year-over-year compared to FY 2024. Operating income came in at $-52M.
In Q3 2025, PRECISION BIOSCIENCES INC reported revenue of $13,000 and earnings per share (EPS) of $-1.84. Net income for the quarter was $-22M. Revenue grew -97.7% year-over-year compared to Q3 2024. Operating income came in at $-21M.
In Q2 2025, PRECISION BIOSCIENCES INC reported revenue of $18,000 and earnings per share (EPS) of $-2.13. Net income for the quarter was $-24M. Revenue grew -100.0% year-over-year compared to Q2 2024. Operating income came in at $-22M.
Over the past 8 quarters, PRECISION BIOSCIENCES INC has experienced revenue contraction from $50M to $636,000. Investors analyzing DTIL stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
DTIL Dividend Yield and Income Analysis
PRECISION BIOSCIENCES INC (DTIL) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
DTIL Momentum and Technical Analysis Profile
PRECISION BIOSCIENCES INC (DTIL) has a momentum factor score of 44/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 40/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 65/100 reflects moderate short selling activity.
DTIL vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, PRECISION BIOSCIENCES INC (DTIL) ranks #187 out of 838 stocks based on the Blank Capital composite score. This places DTIL in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing DTIL against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full DTIL vs S&P 500 (SPY) comparison to assess how PRECISION BIOSCIENCES INC stacks up against the broader market across all factor dimensions.
DTIL Next Earnings Date
No upcoming earnings date has been announced for PRECISION BIOSCIENCES INC (DTIL) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy DTIL? — Investment Thesis Summary
PRECISION BIOSCIENCES INC presents a balanced picture with arguments on both sides. The quality score of 18/100 flags below-average profitability. The value score of 15/100 indicates premium valuation. High volatility (stability score 39/100) increases portfolio risk.
In summary, PRECISION BIOSCIENCES INC (DTIL) earns a Hold rating with a composite score of 32.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on DTIL stock.
Related Resources for DTIL Investors
Explore more research and tools: DTIL vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare DTIL head-to-head with peers: DTIL vs AZN, DTIL vs SLGL, DTIL vs VMD.